In the pooled analyses of the MM Cohort Consortium included 493 MM cases and 978 controls from 8 cohorts, IGF‐1 was found associated with an increased MM risk within 3 years of blood collection while soluble IL‐6 receptor was associated with MM in the 6 first years after blood collection.13 Therefore, these markers are likely to reflect the tumor and/or its microenvironment. Here, IGF1 is linked to Miyoshi myopathy.